Download Claeys CV June 2016 - University of Maryland School of Pharmacy

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
CURRICULUM VITAE
Kimberly C. Claeys, PharmD, BCPS
Assistant Professor Infectious Diseases
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
20 N Pine Street, Baltimore, MD 21201
Office: N432
Phone: 410.706.3215
Fax: 410.706.6580
Email: [email protected]
ACADEMIC & PROFESSIONAL APPOINTMENTS
03/2016 – present
Assistant Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, MD
07/2016 – present
Antimicrobial Stewardship Pharmacist
University of Maryland Medical Center
Baltimore, MD
EDUCATION & PROFESSIONAL TRAINING
07/2013 – 05/2015
Graduate Certificate in Public Health
School of Medicine, Department of Family Medicine and
Public Health Sciences
Wayne State University
Detroit, MI
07/2013 – 02/2016
Post-Doctoral Infectious Diseases Health Outcomes Fellowship
Anti-Infective Research Laboratory
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University
Detroit, MI
Program Director: Michael J. Rybak, PharmD, MPH
07/2012 – 07/2013
ASHP-Accredited PGY1 Pharmacy Residency
University of Illinois at Chicago College of Pharmacy
Chicago, IL
Program Director: Frank P. Paloucek, PharmD, DABAT
09/2008 – 05/2012
Doctor of Pharmacy
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University
Detroit, MI
LICENSURE
04/2016 – present
Maryland Department of Health and Mental Hygiene
Registered Pharmacist License No. 24048
09/2012 – present
Illinois Department of Financial and Professional Regulation
Registered Pharmacist License No. 051296192
CERTIFICATION
09/2015 – present
Antimicrobial Stewardship Certificate Program
Society of Infectious Diseases Pharmacist
Pending completion
11/2013 – present
Board Certified Pharmacotherapy Specialist
Board of Pharmacy Specialties
07/2012 – 07/2013
Resident Teaching Certificate
University of Illinois at Chicago College of Pharmacy
09/2008 – 05/2012
Pharmacy-Based Immunization Delivery
American Pharmacists Association
PROFESSIONAL MEMBERSHIP
National Associations
08/2014 – present
Infectious Diseases Society of America
12/2013 – present
European Society of Clinical Microbiology and Infectious Diseases
07/2013 – present
Society of Infectious Diseases Pharmacists
07/2013 – present
American Society for Microbiology
04/2011 – present
American College of Clinical Pharmacy
12/2010 – present
American Society of Health-System Pharmacists
08/2007 – 05/2012
American Pharmacists Association - Academy of Student Pharmacists
State & Local Associations
04/2016 – present
Maryland Society of Health-System Pharmacists
07/2012 – 07/2013
Illinois Council of Health-System Pharmacists
12/2010 – 05/2012
Phi Lambda Sigma Leadership Society, Gamma Chi Chapter
04/2010 – 05/2012
Rho Chi Academic Honors Society, Alpha Chi Chapter
09/2008 – 09/2012
Michigan Pharmacist Association
INSTITUTIONAL SERVICE
University of Maryland School of Pharmacy, Baltimore, MD
04/2016 – present
Residency Research Committee
04/2016 – present
Pharmacotherapy Pathway Committee – Doctor of Pharmacy Program
Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI
09/2015
Early Academic Admissions Interviewer – Doctor of Pharmacy Program
06/2015 – 01/2016
Faculty Search Committee – Pharmacoepidemiology Faculty Position
KC Claeys CV Page 2 of 12
AWARDS & RECOGNITION
04/2015
Making a Difference in Infectious Disease (MAD-ID)
Travel Grant
06/2014
54th Interscience Conference on Antimicrobial Agents and Chemotherapy
Infectious Disease Fellows Grant Program
02/2014
24th Annual European Congress of Clinical Microbiology and Infectious
Diseases
Travel Grant
06/2013
University of Illinois at Chicago College of Pharmacy
Richard A. Hutchinson Award for Excellence in Pharmacy Practice
05/2012
Eugene Applebaum College of Pharmacy and Health Sciences
Pharmacy Awards and Honors Convocation
Award for Outstanding Professional and Community Service
05/2012
Eugene Applebaum College of Pharmacy and Health Sciences
Pharmacy Awards and Honors Convocation
Natural Standard Research Collaboration Award
11/2011
Southeastern Michigan Society of Health-System Pharmacists
Student Research Award
10/2011
Eugene Applebaum College of Pharmacy and Health Sciences
8th Annual Research Forum
Student Poster Award for Clinical Research
02/2011
Michigan Pharmacists Association
Good Government Award
05/2011, 05/2010,
11/2009
Eugene Applebaum College of Pharmacy and Health Sciences
John Helfman Pharmacy Merit Scholarship
LEADERSHIP EXPERIENCE
09/2013 – 09/2014
Society of Infectious Diseases Pharmacists
Political Advocacy Committee
03/2011 – 03/2012
American Pharmacists Association – Academy of Student Pharmacists
National Policy Standing Committee
02/2011
Michigan Pharmacists Association
Annual Convention and Exhibition Delegate for Wayne State University/House
of Delegates Credentialing Committee
10/2010 – 05/2011
Phi Lambda Sigma Leadership Society – Gamma Chi Chapter
Charter member and member of the Nominations Committee
04/2010 – 04/2011
Student Society of Health-System Pharmacists – Wayne State University
Wayne State University Chapter, Member of Charter Board of Directors
10/2009 – 03/2011
American Pharmacists Association – Academy of Student Pharmacists
Wayne State University Chapter, Student Political Advocacy Network Chair
KC Claeys CV Page 3 of 12
PHARMACY PRACTICE EXPERIENCE
University of Maryland Medical Center, Baltimore, MD
07/2016 – present
Antimicrobial Management Subcommittee
Detroit Medical Center, Detroit Receiving Hospital, Detroit, MI
01/2015 – 01/2016
Antimicrobial Stewardship Committee
02/2014 – 12/2015
Infectious Diseases Consult
Preceptor: Michael J. Rybak, PharmD, MPH
University of Illinois at Chicago Hospital and Health Sciences System, Chicago, IL
07/2012 – 07/2013
PharmD On Call Program
Preceptor: Frank P. Paloucek, PharmD, DABAT
07/2012 – 07/2013
HIV Telemedicine Clinic
Preceptor: Melissa Badowski, PharmD, BCPS, AAHIVE
11/2012 – 12/2012
Infectious Diseases Consult
Preceptor: Larry H. Danziger, PharmD, FIDSA
TEACHING AND PRECEPTING EXPERIENCE
Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI
09/2014 – 02/2016
Small Group-Based Learning Facilitator
PHA 5175 Pharmacotherapeutic Problem Solving
05/2014 – 02/2016
Research Co-Preceptor
FPH 8990 Master’s Project (MPH)
05/2014 – 09/2014
Research Co-Preceptor
PPR 5990 Directed Study in Pharmacy Practice
01/2013 – 02/2015
Didactic Lecturer
PHA 4210 Pharmacotherapy Module: Infectious Diseases
Detroit Medical Center, Detroit Receiving Hospital, Detroit, MI
02/2014 – 12/2015
Clinical Preceptor
Infectious Diseases Consult Rotation
University of Illinois at Chicago College of Pharmacy, Chicago, IL
06/2013
Large Group-Based Learning Facilitator
PHAR 357 Experiential V (Infectious Diseases)
Pneumonia and Urinary Tract Infections Review
04/2013
Didactic Lecturer
Pharmacy Grand Rounds
Major Epidemics Through History
02/2013
Faculty Moderator
PMPR 385 Case-Based Infectious Diseases
MRSA, hVISA, VISA and VRSA
KC Claeys CV Page 4 of 12
RESEARCH EXPERIENCE
06/2016 – present
Respiratory Viral Panel (RVP) diagnostic testing utilization and association
with antibiotic use among hospitalized patients
Funding: None
Role: Co-investigator, data generation and analysis, abstract and manuscript
generation
05/2016 – present
Examining the role of novel risk scoring tools in determining risk of
resistant organisms in pneumonia presenting from the community: Are
they better than the current HCAP criteria?
Funding: None
Role: Co-investigator, data generation and analysis, abstract and manuscript
generation
05/2016 – present
Assessing Clinical Outcomes in Colistin versus Polymyxin B
Funding: None
Role: Co-investigator, data generation and analysis, abstract and manuscript
generation
04/2016 – present
Diagnosis and Management of Complicated Urinary Tract Infections
(cUTIs) Presenting from Long Term Care Facilities: What are the Standards
of Care?
Funding: Submitted to MAD-ID Research Network ($29,169.50) pending
Role: Primary investigator primary study development, grant writer, data
collection and analysis, abstract and manuscript generation
04/2016 – present
Dalbavancin Treatment Pathway to Improve Clinical and Economic
Outcomes in Complicated Skin and Skin Structure Infections Presenting to
the Emergency Department
Funding: Submitting to Allergan Plc
Role: Primary investigator primary study development, grant writer, data
collection and analysis, abstract and manuscript generation
03/2016 – present
Improving antimicrobial stewardship by better predicting risk of multidrug resistant infection among hospitalized community-acquired and
healthcare-associated pneumonia
Funding: Submitted to ACCP Mentored Research Program ($50,000.00) pending
Role: Primary investigator primary study development, grant writer, data
collection and analysis, abstract and manuscript generation
02/2016 – present
Impact of a Pharmacist-Driven Care Package on Staphylococcus aureus
Bacteremia Management in a Large Community Hospital
Funding: None
Role: Co-Investigator, statistical analysis and manuscript generation
11/2015 – 02/2016
Use of rapid diagnostics and predictive modeling for MRSA acute bacterial
skin and skin structure infections (ABSSSIs) to optimize antibiotic therapy
and cost of care in the Emergency Department and Observation Unit
Funding: The Urban Center for Antimicrobial Resistance Discovery Education
and Stewardship (UCARDES) Program, Wayne State University ($50,000)
Role: Co-primary investigator, primary study development, grant writer, data
collection and analysis, abstract and manuscript generation
KC Claeys CV Page 5 of 12
12/2014 – present
Derivation and validation of a risk assessment tool for methicillinresistant S. aureus acute bacterial skin and skin structure infections
(ABSSSIs)
Funding: Bayer International ($194,645.75)
Role: Co-investigator, primary grant writer and study development, data
collection and analysis, assist with app development, abstract and manuscript
generation
11/2014 – 02/2016
Clinical and economic outcomes of acute bacterial skin and skin structure
infections (ABSSSIs): focus on those at risk for methicillin-resistant S.
aureus
Funding: Forest Laboratories/Actavis ($137,486.90)
Role: Co-investigator, primary grant writer and study development, data
collection and analysis, assist with app development, abstract and manuscript
generation
10/2014 – 06/2015
Length of enterococcal bacteremia and associated clinical outcomes
Funding: None
Role: Co-primary investigator, primary study development, data collection and
analysis, abstract and manuscript generation
09/2014 – 11/2015
Deriving a clinically useful severity scoring system in acute bacterial skin
and skin structure infections (ABSSSIs) for determination of admission
requirements
Funding: None
Role: Co-primary investigator, primary study development, data collection and
analysis, abstract and manuscript generation
01/2014 – 10/2014
Improving hospital-based antimicrobial prescribing through a multisystem review of antibiotic utilization patterns
Funding: Michigan Department of Community Health ($260,263.00)
Role: Co-investigator, grant development, large database analysis, abstract
generation
12/2013 – 07/2015
Burden of illness with acute bacterial skin and skin structure infections
discharged from the emergency department or observation unit:
Experience at the Detroit Medical Center
Funding: None
Role: Co-primary investigator, primary study development, data collection and
analysis, abstract and manuscript generation
09/2013 – 07/2015
Clinical outcomes in patients with vancomycin heteroresistant S. aureus
(hVISA) nosocomial lower respiratory tract infections
Funding: None
Role: Co-primary investigator, primary study development, data collection and
analysis, abstract and manuscript generation
09/2013 – 06/2016
Patient outcomes and burden of illness of Gram-negative lower
respiratory infections in intensive care units
Funding: Cubist Pharmaceuticals/Merck ($151,996.80)
Role: Co-investigator, primary study development, data collection and analysis,
abstract and manuscript generation
08/2013 – 09/2014
Combination daptomycin and trimethoprim/sulfamethoxazole in
methicillin-resistant S. aureus infections
Funding: None
Role: Co-primary investigator, primary study development, data collection and
analysis, abstract and manuscript generation
KC Claeys CV Page 6 of 12
07/2013 – 11/2015
Impact of early daptomycin versus vancomycin therapy for bloodstream
infection caused by methicillin-resistant S. aureus
Funding: Cubist Pharmaceuticals/Merck ($177,792.50)
Role: Co-investigator, data collection and analysis, laboratory assessment of
clinical isolates, abstract and manuscript generation
07/2013 – 02/2016
Prospective evaluation of clinical and economic outcomes of ceftaroline
fosamil for the treatment of acute bacterial skin and skin structure
infections (ABSSSIs) documented or at risk of methicillin-resistant S.
aureus
Funding: Forest Laboratories/Actavis ($363,815.50)
Role: Co-investigator, multi-center study coordinator, account management,
patient enrollment, data collection and analysis
ADVISORY BOARD AND JOURNAL REVIEW
07/2015 – present
Infectious Diseases and Therapy
09/2014 – present
Pharmacotherapy
PUBLICATIONS
Manuscripts in Progress
05/2016
Claeys KC, Liao S, Danziger LH. The Past, Present, and Future of Tigecycline:
What Went Wrong, What Went Right.
11/2015
Claeys KC, Zasowski EJ, Lagnf AM, Hallesy JA, Davis SL, Rybak MJ. Burden of
illness of Gram-negative pneumonia treated in the intensive care unit
09/2015
Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Severity assessment and
level of care in acute bacterial skin and skin structure infections: Utilizing
predictive analytics to improve patient care
08/2015
Claeys KC, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ. Practical
application of risk factors for MRSA Acute Bacterial Skin and Skin Structure
Infections (submitted, International Journal Antimicrobial Agents)
06/2015
Claeys KC, Zasowski EJ, Lagnf AM, Nyguen CT, Nagel JL, Levine DP, Kaye KS,
Davis SL, Rybak MJ. Propensity matched analysis of patients treated with
vancomycin versus daptomycin for methicillin-resistant S. aureus bacteremia
(submitted , Antimicrob Agents Chemother)
Manuscripts in Peer-Reviewed Journals
04/2016
Lagnf AM, Zasowski EJ, Claeys KC, Casapao AM, Rybak MJ. Comparison of risk
factors and outcomes associated with polymicrobial and monomicrobial
enterococcal infections. Am J Infect Control. 2016 April 11; PMID: 27079241
03/2016
Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence:
The impact of delayed antibiotic therapy on outcomes in hospital-onset
enterococcal infections. Clin Infect Dis. 2016 Mar 3. PMID 26945013
01/2016
Claeys KC, Lagnf AM, Hallesy JA, Compton MT, Gravelin AL, Davis SL, Rybak MJ.
Pneumonia caused by methicillin-resistant Staphylococcus aureus: Does
vancomycin heteroresistance matter? Antimicrob Agents Chemother 2016 Jan 4;
60(3):1708-16. PMID: 26729497
KC Claeys CV Page 7 of 12
09/2015
Claeys KC, Zasowski EJ, Lagnf AM, Rybak MJ. Comparison of outcomes between
patients with single versus multiple positive blood cultures for Enterococcus:
Infection or Illusion? Am J Infect Control. 2015 Sep 18. pii: S01966553(15)00849-4. doi:10.1016/j.ajic.2015.08.002. PMID: 26388037
06/2015
Claeys KC, Lagnf AM, Patel TB, Jacob MG, Davis DL, Rybak MJ. Acute bacterial
skin and skin structure infections treated with intravenous antibiotics in the
emergency department or observational unit: Experience at the Detroit Medical
Center. Infect Dis Ther. 2015 Jun; 4(2): 173-86. doi: 10.1007/s40121-015-00697. PMID: 26055392
03/2015
Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ.
Association between vancomycin day one exposure profile and outcomes among
patients with methicillin-resistant Staphylococcus aureus infective endocarditis.
Antimicrob Agents Chemother. 2015 Jun; 59(6): 2978-85. doi:
10.1128/AAC.03970-14. PMID: 25753631
01/2015
Claeys KC, Smith JR, Casapao AM, Mynatt RP, Avery L, Schroff A, Yamamura D,
Davis SL, Rybak MJ. Impact of the combination of daptomycin and
trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant
Staphylococcus aureus infections. Antimicrob Agents Chemother. 2015 Apr;
59(4): 1969-76. doi: 10.1128/AAC.04141-14. PMID: 25605354
12/2014
Claeys KC, Fiorvento AD, Rybak MJ. A review of novel combinations of colistin
and lipopeptide or glycopeptide antibiotics for the treatment of multidrugresistant Acinetobacter baumannii. Infect Dis Ther 2014: 3:69–81. doi:
10.1007/s40121-014-0051-9. PMID: 25475412
04/2014
Smith JR, Claeys KC, Barber KE, Rybak MJ. High-dose daptomycin therapy for
staphylococcal endocarditis and when to apply it. Curr Infect Dis Rep. 2014 Oct;
16(10): 429. doi: 10.1007/s11908-014-0429-6. PMID: 25165017
TEXTBOOK CHAPTERS
12/2014
Smith JR, Claeys KC, Zasowski EJ, Yim J, Rybak MJ (pending publication).
Daptomycin resistance in Gram-positive organisms in Kaye KS (Ed.) Antimicrobial
Drug Resistance: Mechanisms of Drug Resistance. New York, New York: Springer
CONTINUING EDUCATION ARTICLES
06/2015
Rybak JM, Claeys KC. Isavuconazole, a new agent for the treatment of invasive
mold infections. MAD-ID 2015 June; 5(2). ACPE No. 0485-0000-15-018-H01-PA
11/2011
Claeys KC, Dodd P. Continuing Education: New and notable medications
approved in 2010 and 2011. Michigan Pharmacist 2011; 49: 25. ACPE No. 112000-11-009-H01-P
CONTRIBUTED CONTENT
10/2010
Interviewed for: Cobb, J. What’s Most Important? Pharmacists in Michigan
Choose Top Legislative/Regulatory Issues. Michigan Pharmacist 2010; 48:6
KC Claeys CV Page 8 of 12
POSTERS & PRESENTATIONS
Professional International Platform Presentations
06/2016
Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Casapao AM, Davis SL, Rybak MJ.
Predictors of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
(hVISA) among Patients with Methicillin-Resistant Staphylococcus aureus
(MRSA) Infective Endocarditis (IE) [Session 436 - Epidemiology and Control of
MRSA] ASM Microbe, Boston, MA
09/2015
Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Practical application of
risk factors for methicillin-resistant Staphylococcus aureus (MRSA) in the
treatment of antibacterial skin and skin structure infections (ABSSSI) [1828] 55 th
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
San Diego, CA
09/2015
Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, DP Levine, KS Kaye, Rybak MJ.
Propensity Matched analysis of daptomycin versus vancomycin for bloodstream
infections caused by methicillin-resistant Staphylococcus aureus (MRSA) [2762]
55th Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC), San Diego, CA
09/2015
Zasowski EJ, Claeys KC, Lagnf AM, Witt JS, Rybak MJ. Predictors of vancomycinresistant enterococci among patients with community-onset enterococcal
bloodstream infections [3073] 55th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), San Diego, CA
09/2015
Zasowski EJ, Claeys KC, Lagnf AM, Witt JS, Rybak MJ. Linezolid versus high-dose
daptomycin for the treatment of vancomycin-resistant enterococcus bloodstream
infections [3051] 55th Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), San Diego, CA
Professional International Invited Presentations
04/2015
“Developing a risk assessment tool for MRSA ABSSSI”
Bayer International Global Council Meeting, Copenhagen, Denmark
04/2010
“Through patients’ eyes: Advocacy and patient care”
American Pharmacist Association (APhA) Annual National Meeting – APhA
Academy of Student Pharmacists, Round Table Discussion, Washington, DC
Professional International & National Poster Presentations
06/2016
Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Use of Intravenous
versus Oral Antibiotics in the Emergency Department/Observation Unit
(ED/OU) for the Treatment of Acute Bacterial Skin and Skin Structure Infections
(ABSSSIs) [Friday-513] ASM Microbe, Boston, MA
06/2016
Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Predictors Of
Multidrug Resistant (MDR) Pseudomonas Aeruginosa Nosocomial Pneumonia in
the Intensive Care Unit (ICU) [Saturday-381] ASM Microbe, Boston, MA
04/2016
Claeys KC, Levine DP. Length of bacteraemia and mortality in S. aureus infective
endocarditis [6163] 26th European Congress of Clinical Microbiology and
Infectious Disease (ECCMID), Amsterdam, Netherlands
KC Claeys CV Page 9 of 12
04/2016
Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Casapao AM, Davis SL, Rybak MJ.
Relationship between duration of methicillin-resistant Staphylococcus aureus
bloodstream infection and mortality [P0485] 26th European Congress of Clinical
Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands
04/2016
Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Casapao AM, Davis SL, Rybak MJ.
Ceftaroline fosamil for the treatment of methicillin-resistant Staphylococcus
aureus infective endocarditis [6638] 26th European Congress of Clinical
Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands
04/2016
Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Impact of
vancomycin population analysis profile (PAP) minimum inhibitory
concentration (MIC) in high-inoculum methicillin-resistant Staphylococcus
aureus (MRSA) bloodstream infections (BSI) [P0477] 26th European Congress of
Clinical Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands
09/2015
Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Burden of illness with
Gram-negative (GN) lower respiratory infections (LRTIs) admitted to intensive
care units (ICUs) [1792] 55th Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC), San Diego, CA
09/2015
Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Risk Assessment and
severity analysis in acute bacterial skin and skin structure infections (ABSSSIs)
[1840] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC), San Diego, CA
09/2015
Zasowski EJ, Claeys KC, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ.
Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant
Staphylococcus aureus pneumonia [2220] 55th Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA
09/2015
Zasowski EJ, Claeys KC, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ.
Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant
Staphylococcus aureus (MRSA) bloodstream infections (BSI) [2207] 55th
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
San Diego, CA
05/2015
Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Burden of illness
associated with acute bacterial skin and skin structure infections evaluated in
the emergency department (ED) or observation unit (OU): Experience at the
Detroit Medical Center 18th Annual Making a Difference in Infectious Disease
(MAD-ID), Orlando, FL
04/2015
Claeys KC, Lagnf AM, Gravelin A, Hallesy J, Alderson R, Davis SL, Rybak MJ.
Clinical outcomes of patients with heterogeneous vancomycin-intermediate S.
aureus (hVISA) lower respiratory tract infections [P0660] 25th European
Congress of Clinical Microbiology and Infectious Disease (ECCMID), Copenhagen,
Denmark
04/2015
Zasowski EJ, Claeys KC, K. Roberts K, Levine DP, Davis SL, Rybak MJ.
Retrospective evaluation of daptomycin plus ceftaroline fosamil versus DAP plus
sulfamethoxazole/trimethoprim (SMX/TMP) for methicillin-resistant
Staphylococcus aureus bloodstream infections [P0700] 25th European Congress
of Clinical Microbiology and Infectious Disease (ECCMID), Copenhagen, Denmark
04/2015
Claeys KC, Lagnf AM, Rybak MJ. Length of enterococcal bacteremia and
associated clinical outcomes [P0038] 25th European Congress of Clinical
Microbiology and Infectious Disease (ECCMID), Copenhagen, Denmark
KC Claeys CV Page 10 of 12
09/2014
Claeys KC, Casapao AM, Davis DL, Rybak MJ. Burden of illness associated with
acute bacterial skin and skin structure infections evaluated in the emergency
department or observational unit: Experience at the Detroit Medical Center [K1702] 54th Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC), Washington, DC
09/2014
Claeys KC, Nagel JL, Pogue JM, Casapao AM, Finks K, Neuhauser M, Schneider A,
Davis SL, and Rybak MJ. Implementing the National Healthcare Safety Network’s
(NHSN’s) Antimicrobial Use Option to aid in determination of resistance among
key nosocomial pathogens [K-327] 54th Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC
09/2014
Nagel JL, Pogue JM, Claeys KC, Casapao AM, Finks J, Rybak MJ. Utilization of the
Centers for Disease Control and Prevention National Healthcare Safety Network
Antimicrobial Use and Resistance Module (CDC AUR) to compare multicenter
antimicrobial use [K-332] 54th Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC), Washington, DC
05/2014
Claeys KC, Nagel JL, Pogue JM, Casapao AM, Davis DL, Rybak MJ. National
Healthcare Safety Network’s Antibiotic Utilization and Resistance Program 17 th
Annual Making a Difference in Infectious Disease (MAD-ID), Orlando, FL
05/2014
Claeys KC, Casapao AM, Pogue J, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R,
Sherwin R, Hafeez W, Levine D, Kaye K, Delgado G, Giuliano CA, Talka R, Johnson
LB, Davis SL, Rybak MJ. Rapid diagnostic testing with GeneXpert improves
enrollment in a randomized clinical trial for detection of methicillin-resistant S.
aureus in acute bacterial skin and skin structure infections [P1471] 24th
European Congress of Clinical Microbiology and Infectious Disease (ECCMID),
Barcelona, Spain
10/2013
Claeys KC, Casapao AM, Goeff DA, Kaye KS, Levine DP, Davis SL, Rybak MJ.
Daptomycin versus vancomycin for bloodstream infection caused by methicillinresistant Staphylococcus aureus (MRSA): Preliminary results. 10th Annual
Research Forum, Eugene Applebaum College of Pharmacy and Health Sciences,
Detroit, MI
12/2012
Claeys KC, Mucksavage JJ, Tesoro EP, Kim KS, Jennings KA. Effects of intraarterial verapamil on post-angiogram hemodynamics. 2012 University Health
System Consortium (UHC), Las Vegas, NV
09/2011
Rhoney DH, Claeys KC, Parker D, Goodwin HE, Lewin J. National survey of drug
shortages in Neurocritical Care Units (NCCU): Description of shortages with
commonly used agents [S183 154] 8th Annual Neurocritical Care Society
Meeting, Montreal, Canada
09/2011
Rhoney DH, Claeys KC, Parker D, Goodwin HE, Lewin J. A Multi-Centre
Evaluation of the Impact of Drug Shortages in Neurocritical Care (NCCU):
Management Strategies and Resource Utilization. [S189 160] 8th Annual
Neurocritical Care Society Meeting, Montreal, Canada
Professional National And Local Presentations
05/2015
“Skin and Skin Structure Infections: Risk assessment and decision analysis to
improve clinical outcomes”
Annual Infectious Diseases Fellowship Forum, Brainerd, MN
04/2014
“Impact of early daptomycin versus vancomycin in methicillin-resistant
Staphylococcus aureus bacteremia”
Annual Infectious Diseases Fellowship Forum, Captiva Island, FL
KC Claeys CV Page 11 of 12
05/2013
“Early use of daptomycin versus vancomycin for methicillin-resistant
Staphylococcus aureus bacteremia with vancomycin minimum inhibitory
concentration >1 mg/L: A matched cohort study”
Pharmacy Critical Care Journal Club, University of Illinois at Chicago, Chicago, IL
05/2013
“Comparative effectiveness of nafcillin or cefazolin versus vancomycin in
methicillin-susceptible Staphylococcus aureus bacteremia”
Pharmacy Critical Care Journal Club, University of Illinois at Chicago College of
Pharmacy, Chicago, Illinois
05/2013
03/2013
“Gram-negative resistance – ESBL, Amp C and KPC”
Noon-Report PGY1 Pharmacy Residents and in-service to surgical intensive care
residents
University of Illinois at Chicago College of Pharmacy & University of Illinois
Hospital & Health Sciences System, Chicago, Illinois
09/2012
“Management of status epilepticus”
Pharmacy Critical Care Journal Club, University of Illinois at Chicago College of
Pharmacy, Chicago, Illinois
08/2011

10/2010
“Early versus late initiation of parenteral nutrition in critically ill adults”
Pharmacy Critical Care Journal Club, Detroit Receiving Hospital, Detroit,
Michigan


“Policy and advocacy: A student’s perspective”
PPR 3020: Introduction to Patient Care
Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan


“Why is policy and advocacy important?”
Wayne State University APhA-ASP
Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan
09/2010

KC Claeys CV Page 12 of 12
Related documents